Corona virus disease 2019 (COVID-19). Coronavirus infection, unspecified
Conditions
Interventions
Intervention 1: Intervention group: In the case group, patients will receive 25 mg losartan tablets two times daily. Intervention 2: Intervention group: Patients will receive 5 mg amlodipine daily.
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Laboratory (RT-PCR of oropharyngeal swab) confirmed COVID-19 Stable hemodynamic condition Blood pressure =130/85 mmHg
Exclusion criteria
Exclusion criteria: Patient's critical condition Cough exacerbation after initiating Losartan Increasing blood potassium levels or high baseline potassium levels New anemia Shock or decreasing blood pressure = 90/60 mmHg after Losartan initiating Angioedema Acute hepatic failure Acute renal failure Bilateral renal artery stenosis History of uncontrolled hypertension Pregnancy and lactation History of treatment with ACE inhibitors and ARB inhibitors Treatment with phenobarbital, rifampin and fluconazole
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mortality. Timepoint: 28 days. Method of measurement: Number of death.;Performance of patients. Timepoint: Primary and 14 days after. Method of measurement: Sequential Organ Failure Assessment (SOFA) Respiratory Score.;Length of hospitalization. Timepoint: 28 days. Method of measurement: Days between admission to discharge.;Laboratory Findings. Timepoint: Primary and 14 days after. Method of measurement: Laboratory methods. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactArmin Sadeghi
Tabriz University of Medical Sciences
Outcome results
None listed